InicioP8A • SGX
add
Cordlife Group Ltd
Cierre anterior
0,15 $
Intervalo diario
0,14 $ - 0,15 $
Intervalo anual
0,13 $ - 0,33 $
Cap. bursátil
38,80 M SGD
Volumen medio
14,30 mil
Relación precio-beneficio
-
Rentabilidad por dividendo
-
Bolsa de valores principal
SGX
En las noticias
Datos financieros
Estado de resultados
Ingresos
Ingresos netos
| (SGD) | sept 2025info | Cambio interanual |
|---|---|---|
Ingresos | 10,21 M | 0,82 % |
Gastos operativos | 9,29 M | 13,72 % |
Ingresos netos | -2,48 M | -59,17 % |
Margen de beneficio neto | -24,32 | -57,82 % |
Beneficios por acción | — | — |
EBITDA | -2,17 M | -78,42 % |
Tipo impositivo efectivo | -6,39 % | — |
Balance general
Activos totales
Responsabilidades totales
| (SGD) | sept 2025info | Cambio interanual |
|---|---|---|
Efectivo y a corto plazo | 43,07 M | — |
Activos totales | 206,80 M | — |
Responsabilidades totales | 97,27 M | — |
Patrimonio total | 109,53 M | — |
Acciones en circulación | 256,31 M | — |
Precio-valor contable | 0,35 | — |
Rentabilidad económica | -3,91 % | — |
Retorno sobre capital | -7,22 % | — |
Flujo de caja
Variación neta del flujo de caja
| (SGD) | sept 2025info | Cambio interanual |
|---|---|---|
Ingresos netos | -2,48 M | -59,17 % |
Efectivo de operaciones | 1,44 M | 126,87 % |
Efectivo de inversión | 12,82 M | 130,42 % |
Efectivo de financiación | -1,50 M | -128,01 % |
Variación neta del flujo de caja | 12,82 M | 7.552,91 % |
Flujo de caja libre | 80,25 mil | — |
Información sobre la empresa
Incorporated in May 2001, Cordlife Group Limited, is a consumer health company and one of the leading providers of cord blood and cord lining banking services in Asia. Cordlife has been listed on the mainboard of SGX since March 2012.
The Group owns the largest network of cord blood banks in Asia with full stem cell processing and storage facilities in six key markets namely Singapore, Hong Kong, India, Indonesia and the Philippines. Beyond cord blood and cord lining banking, Cordlife offers a comprehensive suite of diagnostics services, particularly for the mother and child segment, including urine-based newborn metabolic screening, non-invasive prenatal testing, paediatric vision screening and family genetic screening services.
In January 2018, Cordlife acquired HealthBaby Biotech Co., Limited, the largest private cord blood bank in Hong Kong. Through its majority-owned subsidiary, Stemlife Berhad in Malaysia, Cordlife controls an indirect stake in Thailand's largest private cord blood bank, Thai Stemlife. Cordlife is also the first Singapore private cord blood bank to provide cord blood and cord lining banking services in Myanmar and Vietnam. Wikipedia
Director ejecutivo
Fundación
2 may 2001
Sitio web
Empleados
111
